How long should I take Lenvatinib?

How long lenvatinib takes to work depends on the type of cancer, how advanced it is, past treatments, and the patient's current health. Many trials reported differences in progression-free survival or overall survival at the end of a set time frame, but analysis of various outcomes (such as Kaplan-Meier curves) showed that lenvatinib appeared to start working after 2 months in cancers such as thyroid, renal cell, and endometrial cancer. The length of time you take lenvatinib may be affected by the number and severity of side effects experienced.

There was a difference in progression-free survival (PFS) at two months between 261 patients who received lenvatinib for thyroid cancer and 131 patients who received placebo (out of a total of 392 patients). Overall, participants who received lenvatinib lived an average of 14.7 months longer than those who took placebo, with reported disease-free survival of 18.3 months compared to 3.6 months in the placebo group. In thyroid cancer treatment, 18% of patients permanently discontinue treatment due to severe side effects.

For renal cell carcinoma, there was a difference in PFS at 2 months when lenvatinib was combined with everolimus(L+E). PFS for patients who received L+E was 14.6 months (range, 5.9 to 20.1 months), compared with 5.5 months (range, 3.5 to 7.1 months) for patients who received everolimus alone. The combination reduced the risk of disease progression or death by 63% compared with everolimus alone. For kidney cancer, 29% of patients discontinued treatment due to side effects.

For endometrial cancer, there was a difference in PFS at 2 months when lenvatinib was combined with pembrolizumab, with an overall response rate of 38.3% (range, 29% to 49%), a partial response rate of 27.7%, and a complete response rate of 10.6%. 69% of patients had responses that lasted 6 months or longer. In the endometrial cancer study, 21% of patients discontinued treatment due to serious side effects. Fatal adverse reactions occurred in 3% of patients.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatiniboriginal drug currently marketed overseas, specificationsThe price of each box of 4mg*30 tablets may be more than 1,000 yuan (the price may fluctuate due to exchange rate effects). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be RMB 800 (the price may fluctuate due to exchange rates).